SPECTRAL AI INC. overview

DALLAS, March 24, 2025 (GLOBE NEWSWIRE) -- Spectral AI, Inc. (NASDAQ: MDAI) ("Spectral AI" or the "Company"), a leading developer of the AI-driven DeepView® System, which uses multi-spectral imaging and AI algorithms to predict burn healing potential, today announced the successful completion of a debt financing agreement of up to $15.0 million in funding from Avenue Venture Opportunities Fund II, L.P., a fund of Avenue Capital Group, with an initial draw down of $8.5 million. In connection...

DALLAS, March 20, 2025 (GLOBE NEWSWIRE) -- Spectral AI (NASDAQ: MDAI) (“Spectral AI” or the “Company”) , developer of the AI-driven DeepView ® System, which received Breakthrough Device Designation from the U.S. Food and Drug Administration in 2018 and uses multi-spectral imaging and AI algorithms to predict burn healing potential, today announced that its wholly-owned subsidiary, Spectral IP, Inc., has publicly filed a registration statement with the U.S. Securities and Exchange...

DeepView ® System outperforms burn physicians in identifying non-healing tissue Landmark Burn Validation Study, one of the largest in U.S. history, confirms DeepView’s performance Spectral AI plans FDA submission by mid-2025, targeting De Novo Clearance and rapid commercialization to transform burn care DALLAS, March 17, 2025 (GLOBE NEWSWIRE) -- Spectral AI (NASDAQ: MDAI) (“Spectral AI” or the “Company”) , developer of the AI-driven DeepView ® System, that uses multi-spectral imaging...

DALLAS, March 06, 2025 (GLOBE NEWSWIRE) -- Spectral AI (NASDAQ: MDAI) (“Spectral AI” or the “Company”) , developer of the AI-driven DeepView® System, which received Breakthrough Device Designation from the U.S. Food and Drug Administration (“FDA”) in 2018 and uses multi-spectral imaging and AI algorithms to predict burn healing potential, today announced the completion of the installation of three of the DeepView System devices in Australia. The Company, in partnership with global...

DALLAS, Feb. 28, 2025 (GLOBE NEWSWIRE) -- In a release issued under the same headline earlier today by Spectral AI, Inc. (NASDAQ: MDAI), the reporting date of the financial results for the fourth quarter was incorrectly stated, and has been amended. The corrected release follows: Spectral AI (NASDAQ: MDAI) (“Spectral AI” or the “Company”) , developer of the AI-driven DeepView® System, which received Breakthrough Device Designation from the U.S. Food and Drug Administration (“FDA”)...

DALLAS, Feb. 28, 2025 (GLOBE NEWSWIRE) -- Spectral AI (NASDAQ: MDAI) (“Spectral AI” or the “Company”) , developer of the AI-driven DeepView ® System, which received Breakthrough Device Designation from the U.S. Food and Drug Administration (“FDA”) in 2018 and uses multi-spectral imaging and AI algorithms to predict burn healing potential, today announced that it will report financial results for the fourth quarter and full year ended December 31, 2024 on Wednesday, March 27, 2025...

DALLAS, Feb. 18, 2025 (GLOBE NEWSWIRE) -- Spectral AI (NASDAQ: MDAI) (“Spectral AI” or the “Company”) , developer of the AI-driven DeepView ® System, which received Breakthrough Device Designation from the U.S. Food and Drug Administration (“FDA”) in 2018 and uses multi-spectral imaging and AI algorithms to predict burn healing potential, today announced the satisfaction of its final remaining obligations under the Company’s debt facility with Yorkville Advisors. The Company...

DALLAS, Feb. 07, 2025 (GLOBE NEWSWIRE) -- Spectral AI (NASDAQ: MDAI) (“Spectral AI” or the “Company”) , developer of the AI-driven DeepView ® System, which received Breakthrough Device Designation from the U.S. Food and Drug Administration (“FDA”) in 2018 and uses multi-spectral imaging and AI algorithms to predict burn healing potential, today announced the completion of its data analytics for its U.S. Burn Pivotal Study. One of the largest domestic burn studies ever conducted, the...